BSE filing, BSE: 544759. Summary written from the filing by ALFA Finder's alert engine.
Goldline Pharmaceutical Ltd: key numbers
- Share price
- ₹30.50
- Market cap
- ₹29.28 Cr
- Revenue (annual)
- ₹31.20 Cr
- Net profit (annual)
- ₹4.12 Cr
- P/E (TTM)
- 7.1×Sector 46.1×
- Promoter holding
- 59.54%
- FII holding
- 0.31%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Goldline Pharmaceutical Ltd
All →Goldline Pharmaceutical Annual General Meeting
Goldline Pharmaceutical Ltd held its 22nd Annual General Meeting on August 29, 2026, where directors and key management presented financial performance and future business outlook.
Goldline Pharmaceutical Promoter Buying
Promoter Swapan Khandelwal increased his stake in Goldline Pharmaceutical Limited by 0.81% through an open market acquisition of 78,000 shares.
Goldline Pharmaceutical Other Announcement
Goldline Pharmaceutical Ltd announced the closure of its Register of Members and Share Transfer Books from August 23 to August 29, 2026, for its AGM.
Goldline Pharmaceutical Annual Report
Goldline Pharmaceutical Limited submitted its Annual Report for the financial year 2025-26, including the notice for the upcoming AGM on August 29, 2026.
Goldline Pharmaceutical Annual General Meeting
Goldline Pharmaceutical Limited has issued a notice for its 22nd Annual General Meeting, scheduled for August 29, 2026. The meeting will address financial statements, dividends, and director re-appointments.
Goldline Pharmaceutical Capital Structure Change
Executive Director Mr. Prashant Shrikrishna Karkare acquired 27,000 equity shares of Goldline Pharmaceutical via an open market purchase. This is a non-promoter insider transaction.
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.